PRTN3 and rheumatoid arthritis: Moreover, the comprehension that DAS levels at 4 months are predictive for the ability to achieve SDFR over time in ACPA-negative RA patients can be important for clinicians, as it can contribute to the selection of RA patients eligible for DMARD discontinuation.